Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Non-coding RNAs in AMI Patients: A Substudy of the PACMAN-AMI Trial

CONCLUSIONS: Among AMI patients receiving DAPT with a potent P2Y12 inhibitor, alirocumab had no significant effect on platelet reactivity as assessed by PRU and platelet-derived non-coding RNAs.PMID:37595625 | DOI:10.1055/a-2156-7872

Source: Thrombosis and Haemostasis - August 18, 2023 Category: Hematology Authors: Yasushi Ueki Jonas H äner Sylvain Losdat Giuseppe Gargiulo Hiroki Shibutani Sarah B är Tatsuhiko Otsuka Raminta Kavaliauskaite Vera Mitter Fabrice Temperli David Spirk Stefan Stortecky George Siontis Marco Valgimigli Stephan Windecker Clemens Gutmann Ko Source Type: research